Disc Medicine (IRON) Share-based Compensation (2020 - 2026)
Disc Medicine (IRON) reported Share-based Compensation of $11.9 million for Q1 2026, up 87.74% year-over-year from $6.4 million in Q1 2025, and up 18.95% on a QoQ basis from $10.0 million in Q4 2025.
Disc Medicine (IRON) has 7 years of Share-based Compensation data on file, last reported at $11.9 million in Q1 2026.
- Quarterly Share-based Compensation rose 87.74% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.9 million (up 108.8% YoY) and the FY2025 annual result came in at $34.3 million, up 104.22% from the prior year.
- Share-based Compensation grew to $11.9 million in Q1 2026 per IRON's latest filing, from $10.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $11.9 million in Q1 2026 and bottomed at $332000.0 in Q1 2022.
- The 5-year median for Share-based Compensation is $4.1 million (2024), against an average of $4.2 million.
- The widest annual swing landed in 2022, when Share-based Compensation slumped 86.65%; it then surged 296.29% in 2024.
- Tracing IRON's Share-based Compensation over 5 years: stood at $993000.0 in 2022, then soared by 94.06% to $1.9 million in 2023, then soared by 124.91% to $4.3 million in 2024, then soared by 131.73% to $10.0 million in 2025, then grew by 18.95% to $11.9 million in 2026.
- Per Business Quant, the three latest IRON Share-based Compensation figures stand at $11.9 million (Q1 2026), $10.0 million (Q4 2025), and $9.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | 11.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.95 Mn |
| Mar 31, 2026 | 11.95 Mn |
| Dec 31, 2025 | 10.04 Mn |
| Dec 31, 2025 | 10.04 Mn |
| Sep 30, 2025 | 9.51 Mn |
| Sep 30, 2025 | 9.51 Mn |
| Jun 30, 2025 | 8.42 Mn |
| Jun 30, 2025 | 8.42 Mn |
| Mar 31, 2025 | 6.36 Mn |
| Mar 31, 2025 | 6.36 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Dec 31, 2024 | 4.33 Mn |
| Sep 30, 2024 | 4.33 Mn |
| Sep 30, 2024 | 4.33 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Jun 30, 2024 | 4.09 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Mar 31, 2024 | 4.06 Mn |
| Dec 31, 2023 | 1.93 Mn |
| Dec 31, 2023 | 1.93 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 1.31 Mn |
| Mar 31, 2023 | 1.02 Mn |
| Mar 31, 2023 | 1.02 Mn |
| Dec 31, 2022 | 993,000.00 |
| Dec 31, 2022 | 993,000.00 |
| Sep 30, 2022 | 382,000.00 |
| Sep 30, 2022 | 382,000.00 |
| Jun 30, 2022 | 382,000.00 |
| Jun 30, 2022 | 382,000.00 |
| Mar 31, 2022 | 332,000.00 |
| Mar 31, 2022 | 332,000.00 |
| Dec 31, 2021 | -5.61 Mn |
| Dec 31, 2021 | -5.61 Mn |
| Sep 30, 2021 | 1.66 Mn |
| Sep 30, 2021 | 1.66 Mn |
| Jun 30, 2021 | 2.86 Mn |
| Jun 30, 2021 | 2.86 Mn |
| Mar 31, 2021 | 1.59 Mn |
| Mar 31, 2021 | 1.59 Mn |
| Dec 31, 2020 | 590,000.00 |
| Dec 31, 2020 | 590,000.00 |
| Sep 30, 2020 | 161,000.00 |
| Sep 30, 2020 | 161,000.00 |
| Jun 30, 2020 | 138,000.00 |
| Jun 30, 2020 | 138,000.00 |
| Mar 31, 2020 | 94,000.00 |
| Mar 31, 2020 | 94,000.00 |